Corticosteroids for treatment of COVID-19: effect, evidence, expectation and extent
Abstract Background The World Health Organization (WHO) announced the COVID-19 occurrence as a global pandemic in March 2020. The treatment of SARS-CoV-2 patients is based on the experience gained from SARS-CoV and MERS-CoV infection during 2003. There is no clinically accepted therapeutic drug(s) a...
Guardado en:
Autores principales: | Vijay K. Patel, Ekta Shirbhate, Preeti Patel, Ravichandran Veerasamy, Prabodh C. Sharma, Harish Rajak |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
SpringerOpen
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/76a6df4303d84a6db49bc8c6a9351c9b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A comparative study of the efficacy and outcome of methylprednisolone and dexamethasone in moderate to severe COVID-19 disease
por: Praveen B Gautam, et al.
Publicado: (2021) -
Dismal Survival in COVID-19 Patients Requiring ECMO as Rescue Therapy after Corticosteroid Failure
por: Sebastian Voicu, et al.
Publicado: (2021) -
COMPARISON OF VARIOUS INTRA-ARTICULAR CORTICOSTEROIDS IN KNEE OSTEOARTHRITIS MANAGEMENT
por: Ammara Arif, et al.
Publicado: (2019) -
Comparison of Dexamethasone and Hydrocortisone teratogenic effect on chick embryo
por: SN Ostad, et al.
Publicado: (2000) -
Systemic corticosteroids for management of ‘long-COVID’: an evaluation after 3 months of treatment
por: Nitin Goel, et al.
Publicado: (2021)